AC
ITCI

Ascend Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ascend Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-81,231
Closed -$1.48M – 223
2014
Q1 		$1.48M Buy
+81,231
New +$1.47M 0.04% 172

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Ascend Capital's ITCI Position: Q2 2014 in Review

Ascend Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2014, closing a stake of 81,231 shares — an estimated $1.48M sold.

Ascend Capital first reported a position in ITCI in Q1 2014 and held it in 1 quarter. The position peaked at $1.48M in Q1 2014. 55 funds tracked by Wall St. Rank hold ITCI as of Q2 2014.

  • Ascend Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2014 after selling out during the quarter.
  • Ascend Capital sold 81,231 Intra-Cellular Therapies Inc. shares in Q2 2014, an estimated $1.48M.
  • Ascend Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 1 quarter.
  • Ascend Capital's Intra-Cellular Therapies Inc. position peaked at $1.48M in Q1 2014.
  • 55 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2014.

Based on Ascend Capital's 13F filing for Q2 2014, filed 13 Aug 2014.